

Gunnar Folprecht

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6855902/publications.pdf>

Version: 2024-02-01

125
papers

15,061
citations

66315

42
h-index

20343

116
g-index

130
all docs

130
docs citations

130
times ranked

14967
citing authors

#	ARTICLE	IF	CITATIONS
1	The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). <i>Clinical Colorectal Cancer</i> , 2022, 21, 170-174.	1.0	17
2	Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 102, 102301.	3.4	17
3	Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2022, 8, e215445.	3.4	127
4	Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment. <i>Journal of Pathology</i> , 2022, 257, 607-619.	2.1	13
5	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (<scp>LICC</scp>, <scp>CELM</scp>, <scp>FIRE</scp>). <i>International Journal of Cancer</i> , 2022, 150, 1341-1349.	2.3	6
6	Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: A non-randomized, monocentric phase III clinical trial (PaCa-DD-041 (Eudra-CT) Tj ETQq0 0 0 ngBT / Overdack 10 Tf		
7	Tumor Response and Symptom Palliation from RAINBOW , a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. <i>Oncologist</i> , 2021, 26, e414-e424.	1.9	4
8	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. <i>British Journal of Cancer</i> , 2021, 124, 721-727.	2.9	5
9	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , 2021, 144, 101-112.	1.3	18
10	Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. <i>European Journal of Cancer</i> , 2021, 144, 281-290.	1.3	6
11	Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With <i>ETV6-NTRK3</i> Fusion-Positive Carcinoma Harboring the <i>NTRK3</i> ^{G623R} Solvent-Front Mutation. <i>JCO Precision Oncology</i> , 2021, 5, 687-694.	1.5	3
12	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	7.7	125
13	Influence of the First Wave of the COVID-19 Pandemic on Cancer Care in a German Comprehensive Cancer Center. <i>Frontiers in Public Health</i> , 2021, 9, 750479.	1.3	9
14	Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 811291.	1.1	2
15	Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper. <i>Oncology Research and Treatment</i> , 2020, 43, 628-636.	0.8	48
16	Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306. <i>Annals of Surgical Oncology</i> , 2020, 27, 2389-2401.	0.7	16
17	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <i>JCO Precision Oncology</i> , 2020, 4, 116-127.	1.5	4
18	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: <i>Post hoc</i> Analysis of the MOSAIC and PETACC-8 Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1153-1161.	1.1	14

#	ARTICLE	IF	CITATIONS
19	Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer. <i>Cancer Communications</i> , 2019, 39, 74.	3.7	24
20	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 420-435.	5.1	191
21	Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. <i>Journal of Clinical Oncology</i> , 2019, 37, 3212-3222.	0.8	333
22	Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. <i>International Journal of Cancer</i> , 2019, 145, 2282-2291.	2.3	21
23	Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. <i>Lancet</i> , The, 2019, 393, 1948-1957.	6.3	1,494
24	Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc+ Monocytes in Rectal Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 602.	2.2	8
25	Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3520-3520.	0.8	4
26	Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4120-4120.	0.8	2
27	Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).. <i>Journal of Clinical Oncology</i> , 2019, 37, 571-571.	0.8	1
28	Place of death and chemotherapy use at the end of life in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e23006-e23006.	0.8	0
29	Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).. <i>Journal of Clinical Oncology</i> , 2019, 37, e15025-e15025.	0.8	0
30	Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3583-3583.	0.8	0
31	Abstract 468: Clinical relevance of comprehensive genomic analysis in advanced-stage cancers and rare malignancies: Results from the MASTER trial of the German Cancer Consortium. , 2019, , .		0
32	Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer. <i>Oncolimmunology</i> , 2018, 7, e1393133.	2.1	17
33	Immunotherapy of Colon Cancer. <i>Oncology Research and Treatment</i> , 2018, 41, 282-285.	0.8	33
34	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 379.	3.4	104
35	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With <i>RAS</i> and <i>BRAF</i> Mutational Status. <i>JAMA Oncology</i> , 2018, 4, e173695.	3.4	55
36	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	1.5	20

#	ARTICLE	IF	CITATIONS
37	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 4745-4753.	3.2	23
38	Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial. <i>Annals of Oncology</i> , 2018, 29, 1793-1799.	0.6	28
39	Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 59-59.	0.8	5
40	Acute ischaemic stroke and myocardial infarction after chemotherapy with vinorelbine for non-small cell lung cancer: a case report. <i>Journal of Chemotherapy</i> , 2017, 29, 49-53.	0.7	7
41	DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. <i>Nature Communications</i> , 2017, 8, 14093.	5.8	85
42	Adjuvant FOLFOX +/âˆ² cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients. <i>Annals of Oncology</i> , 2017, 28, 824-830.	0.6	38
43	Prognostic Value of <i>BRAF</i> and <i>KRAS</i> Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw272.	3.0	201
44	Colorectal Liver Metastases: A Critical Review of State of the Art. <i>Liver Cancer</i> , 2017, 6, 66-71.	4.2	69
45	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017, 82, 16-24.	1.3	40
46	Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	466
47	Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor. <i>Nuklearmedizin - NuclearMedicine</i> , 2017, 56, N19-N21.	0.3	2
48	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3515-3515.	0.8	3
49	Abstract LB-287: Identification of patients at risk for tumor predisposition syndromes based on the evaluation of sporadic cancer exome sequencing data: experiences from the NCT/DKTK MASTER program. , 2017, , .		0
50	Liver Metastases in Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e186-e192.	1.8	8
51	Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. <i>Annals of Oncology</i> , 2016, 27, 1273-1279.	0.6	65
52	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. <i>European Journal of Cancer</i> , 2016, 63, 11-24.	1.3	73
53	Prognostic Effect of <i>BRAF</i> and <i>KRAS</i> Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab. <i>JAMA Oncology</i> , 2016, 2, 643.	3.4	125
54	Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2016, 15, e29-e39.	1.0	19

#	ARTICLE	IF	CITATIONS
55	Preoperative chemoradiotherapy and the long-term run in curative treatment of locally advanced oesophagogastric junction adenocarcinoma: Update of the POET phase III study.. Journal of Clinical Oncology, 2016, 34, 4031-4031.	0.8	2
56	Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study.. Journal of Clinical Oncology, 2016, 34, 553-553.	0.8	3
57	Efficacy and safety of first-line cetuximab + FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.. Journal of Clinical Oncology, 2016, 34, 647-647.	0.8	6
58	Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget, 2016, 7, 44322-44329.	0.8	47
59	Germline genetics of cancer of unknown primary (CUP) and its specific subtypes. Oncotarget, 2016, 7, 22140-22149.	0.8	12
60	Differences in gene-expression in mCRC tissue samples with regard to tumor location and used chemotherapeutic substances: Data of the FIRE-1 study.. Journal of Clinical Oncology, 2016, 34, 562-562.	0.8	0
61	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2015, 16, 979-989.	5.1	577
62	Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. British Journal of Cancer, 2015, 113, 1027-1034.	2.9	34
63	Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.. Journal of Clinical Oncology, 2015, 33, 3506-3506.	0.8	2
64	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. Journal of Clinical Oncology, 2015, 33, 3507-3507.	0.8	6
65	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. Journal of Clinical Oncology, 2015, 33, TPS3634-TPS3634.	0.8	2
66	Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAcOLOR platform.. Journal of Clinical Oncology, 2015, 33, 575-575.	0.8	4
67	Detection of tumor progression via cell-free DNA (cfDNA) in patients with colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 598-598.	0.8	2
68	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. Journal of Clinical Oncology, 2015, 33, TPS789-TPS789.	0.8	2
69	Mortality from outpatients chemotherapy (CTx) in patients (pts) with solid tumors.. Journal of Clinical Oncology, 2015, 33, e17676-e17676.	0.8	0
70	Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Annals of Oncology, 2014, 25, 2378-2385.	0.6	93
71	Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. European Journal of Cancer, 2014, 50, 1590-1601.	1.3	55
72	European perspective for effective cancer drug development. Nature Reviews Clinical Oncology, 2014, 11, 492-498.	12.5	42

#	ARTICLE	IF	CITATIONS
73	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 862-873.	5.1	239
74	Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2014, 14, 521.	1.1	32
75	Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). <i>Annals of Oncology</i> , 2014, 25, 1018-1025.	0.6	213
76	Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3549-3549.	0.8	0
77	Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients – an observational study. <i>Experimental & Translational Stroke Medicine</i> , 2013, 5, 7.	3.2	13
78	Patients' perspectives on palliative chemotherapy of colorectal and non - colorectal cancer: a prospective study in a chemotherapy- experienced population. <i>BMC Cancer</i> , 2013, 13, 66.	1.1	14
79	Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. <i>European Journal of Cancer</i> , 2013, 49, 439-448.	1.3	58
80	Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). <i>Pharmacogenomics Journal</i> , 2013, 13, 410-416.	0.9	14
81	Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. <i>Annals of Oncology</i> , 2013, 24, 1560-1567.	0.6	79
82	Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. <i>British Journal of Cancer</i> , 2012, 107, 1044-1050.	2.9	16
83	Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 679-687.	5.1	585
84	The EORTC Gastrointestinal Tract Cancer Group: 50 years of research contributing to improved gastrointestinal cancer management. <i>European Journal of Cancer</i> , Supplement, 2012, 10, 51-57.	2.2	2
85	O-0024 Phase 2 Randomized, Noncomparative, Open-Label Study of Afibercept and Modified Folfox6 in the First-Line Treatment of Metastatic Colorectal Cancer (AFFIRM). <i>Annals of Oncology</i> , 2012, 23, iv16.	0.6	23
86	Survival with cetuximab/FOLFOX or cetuximab/FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study. <i>Journal of Clinical Oncology</i> , 2012, 30, 540-540.	0.8	8
87	Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 4892-4900.	3.2	119
88	Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. <i>Journal of Clinical Oncology</i> , 2011, 29, 2011-2019.	0.8	1,713
89	Neoadjuvant chemotherapy for non-/resectable metastases. <i>European Journal of Cancer</i> , 2011, 47, S52-S60.	1.3	6
90	Trousseau's syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 715-716.	1.1	10

#	ARTICLE	IF	CITATIONS
91	Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). <i>BMC Cancer</i> , 2011, 11, 509.	1.1	58
92	Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy. <i>Cancer Research</i> , 2011, 71, 5670-5677.	0.4	369
93	Neoadjuvant Therapy in Patients with Pancreatic Cancer: A Disappointing Therapeutic Approach?. <i>Cancers</i> , 2011, 3, 2286-2301.	1.7	3
94	Bevacizumab for recurrent hemangioendothelioma. <i>Acta OncolÃ³gica</i> , 2011, 50, 153-154.	0.8	18
95	Comparison of histopathological and gene expression-based typing of cancer of unknown primary. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 456, 23-29.	1.4	19
96	Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). <i>British Journal of Cancer</i> , 2010, 102, 500-505.	2.9	163
97	EORTC Elderly Task Force expertsâ€™ opinion for the treatment of colon cancer in older patients. <i>Cancer Treatment Reviews</i> , 2010, 36, 83-90.	3.4	64
98	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2010, 11, 38-47.	5.1	873
99	Cetuximab in metastatic colorectal cancer â€œ Author' reply. <i>Lancet Oncology</i> , The, 2010, 11, 314.	5.1	0
100	Phase II Trial of Capecitabine and Oxaliplatin in Patients with Adeno- and Undifferentiated Carcinoma of Unknown Primary. <i>Oncology Research and Treatment</i> , 2009, 32, 162-166.	0.8	10
101	Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. <i>British Journal of Cancer</i> , 2009, 100, 44-49.	2.9	72
102	Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2009, 360, 1408-1417.	13.9	3,543
103	Biologicals for Colorectal Cancer Metastases. , 2009, , 1-7.		0
104	Accomplishments in 2008 in the management of curable metastatic colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, S15-22.	0.8	11
105	Introduction: Advances in treatment of metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2008, 34, S1-S2.	3.4	3
106	Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 1443-1451.	0.8	216
107	Carcinoma of Unknown Primary – an Orphan Disease?. <i>Breast Care</i> , 2008, 3, 3-3.	0.8	12
108	Chemotherapy in Elderly Patients with Colorectal Cancer. <i>Oncologist</i> , 2008, 13, 390-402.	1.9	100

#	ARTICLE	IF	CITATIONS
109	Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 215-223.	3.2	26
110	Metastases in the Absence of a Primary Tumor. <i>Deutsches A&#x0308;rzteblatt International</i> , 2008, 105, 733-40.	0.6	31
111	Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis from Colorectal Cancer. , 2007, 134, 425-440.		34
112	Biomarkers for therapeutic efficacy. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 129-142.	2.2	4
113	Intravitreal bevacizumab and blood pressure: does "safe" mean "safe enough"? <i>Acta Ophthalmologica</i> , 2007, 85, 573-574.	0.4	3
114	Feasibility of High Activity Rhenium-188-Microsphere in Hepatic Radioembolization. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 942-950.	0.6	43
115	Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 268-276.	2.0	63
116	Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. <i>Annals of Oncology</i> , 2006, 17, 450-456.	0.6	211
117	Drug Insight: metastatic colorectal cancer"oral fluoropyrimidines and new perspectives in the adjuvant setting. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 578-587.	4.3	7
118	Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. <i>Annals of Oncology</i> , 2005, 16, 1311-1319.	0.6	560
119	Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. <i>Annals of Oncology</i> , 2004, 15, 1330-1338.	0.6	230
120	The Role of New Agents in the Treatment of Colorectal Cancer. <i>Oncology</i> , 2004, 66, 1-17.	0.9	35
121	Role of new agents in the treatment of colorectal cancer. <i>Surgical Oncology</i> , 2004, 13, 75-81.	0.8	7
122	Argon plasma coagulation of Barrett's esophagus does not influence esophageal motility " A manometry study. <i>Gastroenterology</i> , 2000, 118, A1233.	0.6	1
123	Aldosterone activates the nuclear pore transporter in cultured kidney cells imaged with atomic force microscopy. <i>Pflugers Archiv European Journal of Physiology</i> , 1996, 432, 831-838.	1.3	19
124	Immunolocalization of lamins and nuclear pore complex proteins by atomic force microscopy. <i>Pflugers Archiv European Journal of Physiology</i> , 1995, 430, 795-801.	1.3	31
125	Polarized ion transport during migration of transformed Madin-Darby canine kidney cells. <i>Pflugers Archiv European Journal of Physiology</i> , 1995, 430, 802-807.	1.3	57